Every round on record, with the sources behind each and the investors on them.
A startup focused on treatments for LRRK2-associated Parkinson's disease
anacalypsistherapeutics.comGreeceHealthtechFounded 2019
10 sources · checked 1 time, last 10d ago
Developing: it holds up against its sources so far, and firms up as more reporting lands.
The headlines call it seed funding, but the article text calls it pre-seed financing; the more specific round description wins. The amount was not disclosed.; not on the page it cites, so not applied: date
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Pre-seed | n/a | 2026-09-22 | Metavallon VC | No recent discussion |
10 sources · checked 1 time, last 10d ago [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 4 of 10 sources The headlines call it seed funding, but the article text calls it pre-seed financing; the more specific round description wins. The amount was not disclosed.; not on the page it cites, so not applied: date | ||||
Anacalypsis Therapeutics develops disease-modifying medicines and biomarkers for neurodegenerative diseases, initially Parkinson’s disease, using genetically linked targets and precision neurology.
Checked against 10 sources on Sep 24
Also named as backers in company research: Brain Gain Fund, Michael J. Fox Foundation for Parkinson’s Research (MJFF), egg (enter•grow•go), the Eurobank incubation and acceleration program